These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11383596)

  • 1. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7(2):89-93. PubMed ID: 11383596
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination?
    Reenaers C; Belaiche J; Louis E
    Inflamm Bowel Dis; 2010 Aug; 16(8):1271-2. PubMed ID: 20027649
    [No Abstract]   [Full Text] [Related]  

  • 5. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of infliximab in ulcerative colitis: further questions.
    Lees CW; Shand AG; Penman ID; Satsangi J; Arnott ID
    Inflamm Bowel Dis; 2006 Apr; 12(4):335-7. PubMed ID: 16633056
    [No Abstract]   [Full Text] [Related]  

  • 7. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of chronic inflammatory bowel diseases].
    Stange EF
    Praxis (Bern 1994); 2002 Nov; 91(47):2029-39. PubMed ID: 12501498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease.
    Burger DC; Florin TH
    Inflamm Bowel Dis; 2009 Dec; 15(12):1772. PubMed ID: 19170193
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab.
    Elisa B; Beny L
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):442-3. PubMed ID: 20653912
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of ulcerative colitis with infliximab: are we there yet?
    Fuss IJ
    J Pediatr Gastroenterol Nutr; 2004 Mar; 38(3):247-9. PubMed ID: 15076622
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disseminated salmonella infection with aortic mycotic aneurysm in a ulcerative colitis patient treated with infliximab].
    Corberand D; Bredin C; Gizard E; Sava C; Rey P
    Presse Med; 2013 Dec; 42(12):1658-60. PubMed ID: 23688701
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.